22nd Century Group (XXII) Q1 2025 Earnings Call May 13, 2025 08:00 AM ET Company Participants Matt Kreps - Investor RelationsLarry Firestone - CEO & Chair of the BoardDan Otto - CFO Conference Call Participants Andrew White - Analyst Operator Welcome to twenty second Century Group's First Quarter twenty twenty five Conference Call and Webcast. At this time, all participants have been placed in a listen only mode. It is now my pleasure to turn the floor over to Matt Kreps, Investor Relations for twenty secon ...

22nd Century Group (XXII) Q1 2025 Earnings Call May 13, 2025 08:00 AM ET Speaker0 Welcome to twenty second Century Group's First Quarter twenty twenty five Conference Call and Webcast. At this time, all participants have been placed in a listen only mode. It is now my pleasure to turn the floor over to Matt Kreps, Investor Relations for twenty second Century Group. Please begin. Speaker1 Hello and welcome to twenty second Century's first quarter twenty twenty five results conference call. Joining me today a ...

Core Viewpoint - Achieve Life Sciences plans to submit a New Drug Application (NDA) for cytisinicline to the FDA in June 2025, marking a significant milestone in the development of a new treatment for smoking cessation [1][2]. Company Developments - The company reported financial results for Q1 2025, with cash and equivalents totaling $23.2 million and a net loss of $12.8 million for the quarter [10][20]. - Achieve has successfully completed the FDA's long-term exposure requirements for cytisinicline, demonstrating safety data on over 300 participants completing six months and 100 participants completing one year of treatment [6][8]. - The company conducted a Science Advisory Board (SAB) meeting with leading experts to discuss clinical progress and NDA preparations [9]. Clinical Trial Results - The Phase 3 ORCA-3 trial results published in JAMA Internal Medicine confirmed cytisinicline's efficacy and tolerability, showing reduced nicotine cravings and extended quit rates through 24 weeks [5][8]. - In the ORCA-OL long-term exposure trial, 75% of the 479 enrolled participants remained on treatment, indicating the potential for cytisinicline to shift the treatment paradigm for smoking cessation [4][6]. Market Context - There are approximately 29 million adults in the U.S. who smoke combustible cigarettes, with tobacco use being the leading cause of preventable death [13]. - Cytisinicline has been granted Breakthrough Therapy designation by the FDA, addressing the critical need for effective treatments for nicotine dependence, including e-cigarette cessation [14][15].

Core Insights - 22nd Century Group, Inc. reported a significant sequential sales increase of approximately 50% in Q1 2025, driven by its growth strategy and new sales activities across various product categories [1][3][6] - The company is preparing for the launch of its first VLN partner brand shipments and has made regulatory filings for new products in all 50 states [1][6] - The financial results indicate a reduction in operating loss and net loss compared to the previous quarter, reflecting improved operational efficiency [6][10] Financial Performance - Net revenues for Q1 2025 reached $6.0 million, up from $4.0 million in Q4 2024, marking a 50% increase [6][10] - Gross profit improved to a loss of $(0.6) million from $(1.3) million, while operating expenses decreased to $2.0 million from $2.8 million [6][10] - The operating loss decreased to $(2.6) million from $(4.1) million, and net loss decreased to $(3.3) million from $(4.2) million [6][10] Product Developments - The company launched VLN Red, expanding its reduced nicotine content product line, which already includes VLN Gold and Green [6][12] - New partner branded VLN products are set to be launched, supported by marketing campaigns to enhance sales volumes [3][6] - Shipments of conventional products under a new agreement with Smoker Friendly have commenced, including the launch of Smoker Friendly Black Label cigarettes [6][12] Debt and Liquidity - As of the end of Q1 2025, the company reported net debt of $3.4 million, down from $4.6 million at the end of the previous quarter [6][12] - The company has successfully reduced its total debt by $3.7 million year-to-date while managing working capital needs [12][33]

"中美经贸高层会谈5月10日至11日在瑞士日内瓦举行，中方牵头人表示双方达成重要共识，并于当日发布了联合 声明。由于此次会谈结果超出市场预期，有利于中国纺服出口的恢复，短期内棉花期货价格有望迎来反弹。"中信 建投期货分析师陈家谊接受《华夏时报》记者采访时表示。 中美互降关税利好棉花 5月12日，新华社发布中美日内瓦经贸会谈联合声明，美国将修改2025年4月2日第14257号行政令中规定的对中国 商品（包括香港特别行政区和澳门特别行政区商品）加征的从价关税，其中，24%的关税在初始的90天内暂停实 施，同时保留按该行政令的规定对这些商品加征剩余10%的关税。与此同时，美国取消根据2025年4月8日第14259 号行政令和2025年4月9日第14266号行政令对这些商品的加征关税。 华夏时报（www.chinatimes.net.cn）记者 叶青 北京报道 受中美经贸关系缓和影响，大宗商品市场重拾乐观情绪，其中郑棉期货价格走势尤为强劲。棉花期货主力2509合 约早盘高开高走，一度刷新一个月来高位，日内涨幅为2.44%。棉纱期货价格同样走强，涨幅为1.61%。5月12日 夜盘开盘，棉花期货继续大涨，截至记者发稿时， ...

机器之心报道 具体来讲，CoRT 能让 AI 模型递归地思考它们的响应，生成替代性方案，并从中选择最佳的一个。 这就像赋予了 AI 自我质疑或反驳的能力，并一遍一遍地尝试。 通过将「结构化自我批判」和「递归思考模式」结合起来，提升语言模型的推理能力。 编辑：杜伟 递归思考 + 自我批判，CoRT 能带来 LLM 推理力的飞跃吗？ CoT（Chain-of-thought）大家都很熟悉了，通过模仿「人类解题思路」，进而大幅提升语言模型的推理能力。 这几天，一个名为 CoRT（Chain-of-Recursive-Thoughts）的概念火了！从名称上来看，它在 CoT 中加入了「递归思考」这一步骤。 还有网友指出，这种方法在 2023 年的论文中《Improving Factuality and Reasoning in Language Models through Multiagent Debate》就出现了。 有网友发出疑问：CoRT 不就是现在大多数 LLM 的思考模式吗？ 短短两周时间，CoRT 在 GitHub 的星标数已经快突破 2k 了。 GitHub 地址：https://github.com ...

Core Insights - 22nd Century Group, Inc. has successfully closed the sale of its Needle Rock Farms assets, generating net proceeds of approximately $770,000 after expenses, which will enhance its cash position [1][2] - The sale of these unused assets, previously related to the hemp cannabis business, allows the company to redeploy capital into its growth strategies for 2025, which are already showing positive results [2] - The company plans to report its complete first quarter results on May 13, 2025, along with a conference call on the same day [2] Company Overview - 22nd Century Group is a pioneering company in nicotine harm reduction within the tobacco industry, focusing on enabling smokers to control their nicotine consumption [3] - The flagship product, VLN cigarettes, contains 95% less nicotine than traditional cigarettes and has been proven to significantly reduce nicotine consumption [4] - The company operates a 60,000 square foot manufacturing facility in Mocksville, North Carolina, with the capacity to produce over 45 million cartons of combusted tobacco products annually [5] Technology and Innovation - The proprietary reduced nicotine tobacco blends are developed using patented technologies that regulate nicotine biosynthesis in the tobacco plant, ensuring full flavor and high yield with significantly lower nicotine content [6] - The extensive patent portfolio positions the company as the sole provider of low nicotine combustible cigarettes in the United States and key international markets [6]

Turning Point Brands (TPB) Q1 2025 Earnings Call May 07, 2025 09:30 AM ET Company Participants Andrew Flynn - CFOGraham Purdy - CEO, President & DirectorSummer Frein - Chief Revenue OfficerAaron Grey - Managing Director, Head of Consumer ResearchIan Zaffino - Managing Director Conference Call Participants Eric Des Lauriers - Senior Research AnalystNick Anderson - Director & Research Analyst Operator Good morning, and welcome to the Turning Point Brand Q1 twenty twenty five Conference Call. All participants ...

Financial Data and Key Metrics Changes - Revenue increased by 28% to $106.4 million for Q1 2025, with adjusted EBITDA rising by 12% to $27.7 million [4][13] - Gross margin was 56%, down 220 basis points year over year but flat sequentially [13] - Free cash flow for the quarter was $12.4 million, with capital expenditures of $2.2 million [16] Business Line Data and Key Metrics Changes - Modern Oral revenue reached $22.3 million, with sales increasing nearly 10 times year over year [5][16] - Stoker's revenue increased by 63% to $59.2 million, with MST portfolio net sales growing by 10% to $26.3 million [7][15] - Zig Zag sales increased by 1% year over year to $47.3 million, with gross profit decreasing by 7.2% compared to the prior year [14] Market Data and Key Metrics Changes - The company anticipates the modern oral category will exceed $5 billion in manufacturers' revenue by the end of the decade [5] - The company aims for a long-term target of double-digit market share in the modern oral space [6] Company Strategy and Development Direction - The company is increasing full-year consolidated nicotine pouch sales guidance to a range of $80 million to $95 million from $60 million to $80 million [5][17] - Key initiatives include reallocating sales and marketing resources, increasing sales force headcount, and improving online presence [6][10] - The company is exploring U.S. manufacturing to improve profitability and mitigate supply chain risks [6][7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth of white nicotine pouch brands and the overall modern oral category [5][6] - The company is focused on building brands for the long term and executing against an omnichannel plan [11][12] - Management acknowledged potential headwinds from tariffs and foreign exchange impacts on the Zig Zag segment [17] Other Important Information - The company reaffirmed its previously announced 2025 adjusted EBITDA guidance of $108 million to $113 million [5][17] - Budgeted capital expenditures for 2025 are projected to be between $4 million to $5 million, excluding modern oral business projects [17] Q&A Session Summary Question: Comments on distribution gains in Modern Oral and rollout expectations for ALP - Management noted strong traction with retailers and plans for rollouts and enhancements later in the year [22][23] Question: Capacity to produce nicotine pouches at current facilities - Management confirmed adequate supply and ongoing exploration of onshoring production options [26] Question: Timing impact on pouch shipments and brand awareness for ALP - Management indicated that ALP's rollout is focused on online direct-to-consumer channels and is seeing good brand awareness [30][32] Question: Stoker segment gross margin performance - Management stated that pouch margins are within previously discussed ranges and are performing well [35] Question: Advertising regulations for nicotine pouches - Management acknowledged more flexibility in advertising compared to traditional tobacco products but emphasized responsible marketing [44] Question: Timing of PMTA applications amid FDA changes - Management indicated uncertainty regarding timing due to changes in government but continues to monitor the situation [46]

Year to Date Total Debt Reduction of approximately $3.8 Million MOCKSVILLE, N.C., May 07, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a tobacco products company that is leading the fight against nicotine dependence and believes smokers should have a choice about their nicotine consumption, today announced that has repaid an additional $1 million in debt to its senior lender. The Company's total debt principal outstanding now stands at approximately $3.9 million. "Our debt reduction pro ...